SBRT for oligoprogressive disease: using the evidence to maximise the benefits
Mené aux Etats-Unis sur 106 patients atteints d'un cancer du sein métastatique oligoprogressif ou d'un cancer du poumon non à petites cellules (durée médiane de suivi : 11,6 mois), cet essai randomisé multicentrique de phase II évalue l'efficacité, du point de vue de la survie sans progression, d'une radiochirurgie après un traitement systémique de première intention
The use of stereotactic body radiotherapy (SBRT) in oligometastatic disease is being studied across several primary tumour types and across the breadth of oligometastatic states; 1 however, gathering evidence for the benefit of SBRT has been challenging. Previous studies have shown the effectiveness and safety of SBRT in patients with de-novo metachronous disease 2 and synchronous oligometastatic non-small-cell lung cancer (NSCLC), 3 in the pre-immunotherapy era. However, not all studies of SBRT have shown positive results; for instance, the phase 2/3 NRG-BR002 study of SBRT in patients with de-novo oligometastatic breast cancer did not show an added benefit.
The Lancet , commentaire, 2022